Bruce Horowitz has been appointed chief operating officer, Provectus. Mr. Horowitz previously served as Provectus’ chief operations consultant since 2017. He has also served as a member of the company’s board. Provectus is a clinical-stage biotechnology company developing a new class of drugs for oncology and dermatology based on a wholly-owned family of chemical small molecules called halogenated xanthenes.

Prior to working for Provectus, Mr. Horowitz  served as the managing director of Capital Strategists, LLC, which provides corporate, strategic, and financial consulting services, and an advisor to family trusts and private individuals, with a focus on financial asset management, real estate management, and special situation investments.

Earlier in his career, Mr. Horowitz was a charter member of the New York Futures Exchange, and senior vice president managing principal equity investment accounts, private equity investments and public offerings at Drake Capital Securities, and managed the trading department at the Los Angeles office of Laidlaw Equities.

Ed Pershing, CPA, chair of the company's board, said, “We are thrilled to have Bruce fill this critical leadership position at Provectus. Over the last couple of years, his contribution to reforming the Company’s legacy and inherited corporate governance, business management, and clinical operations issues has been quite consequential. This work ultimately led to realized operational savings of tens of millions of dollars as well as recovery efforts from realized and unrealized judgements and settlements of more than ten million dollars.”